知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

199 条记录 (耗时 0.029 秒)

    Composition containing lutein/lutein ester and applications thereof
    21.
    发明授权
    Composition containing lutein/lutein ester and applications thereof 有权

    公开(公告)号：US10647669B2

    公开(公告)日：2020-05-12

    申请号：US16320712

    申请日：2017-06-14

    申请人： SinoNutraceutical Co., Ltd.

    发明人： Maojian Gu ,  Jianmei Su

    IPC分类号： A61K9/20 ,  C07C403/24 ,  A61P27/02 ,  A23L33/105 ,  A61K47/12 ,  A61K31/23 ,  A61K47/02 ,  A61K31/047 ,  A61K31/015 ,  A61K47/40 ,  A61K47/26 ,  A61P27/12 ,  A61P27/10 ,  A61K9/00

    摘要： Disclosed in the present invention are a composition containing lutein/lutein ester and applications thereof. Components of the composition containing lutein/lutein ester comprise lutein/lutein ester, β-carotene and a pharmaceutically acceptable carrier. The weight ratio of lutein/lutein ester to β-carotene is 1:0.1-100. In the present invention, by cooperatively using lutein/lutein ester and β-carotene and using auxiliary natural healthy ingredients, the dosage form of an orally disintegrating tablet is prepared. The orally disintegrating tablet is absorbed through the oral cavity, has fast effectiveness and small first-pass effect, reduces damage of gastric acid to lutein/lutein ester, has high bioavailability, and has the characteristics of nutritional and health-care effects, good mouthfeel and fast absorption. By eating the product, visual power can be obviously enhanced, the ocular blood flow is increased, and eye muscle fatigue is alleviated, and accordingly the morbidities of cataract, senile niacula lutea retinae lesion and adolescent myopia are reduced.

    QUANTITATIVE LIGANDOMICS FOR SYSTEMATIC IDENTIFICATION OF THERAPEUTIC LIGANDS
    23.
    发明申请
    QUANTITATIVE LIGANDOMICS FOR SYSTEMATIC IDENTIFICATION OF THERAPEUTIC LIGANDS 审中-公开

    公开(公告)号：US20190204302A1

    公开(公告)日：2019-07-04

    申请号：US15860170

    申请日：2018-01-02

    申请人： Wei Li

    发明人： Wei Li

    IPC分类号： G01N33/53 ,  A61P3/10 ,  A61P35/00 ,  C12Q1/02 ,  G01N33/15 ,  C12Q1/68 ,  A61P27/10 ,  C12N15/09 ,  C07K16/28

    摘要： The present invention is directed to methods for systematic identification of cellular ligands, disease-associated ligands, age-related ligands and receptor-specific ligands. Disease-associated ligands are promising targets to develop novel ligand-based therapies. The methods are broadly applicable to any type of cells or diseases in in vitro and in vivo settings. This invention further used the methods to identify Scg3 as a disease-related angiogenic factor for the therapy of diabetic retinopathy, diabetic macular edema, proliferative diabetic retinopathy, vascular age-related macular degeneration, diabetic foot and cancers.

    TREATMENT FOR MYOPIA
    24.
    发明申请
    TREATMENT FOR MYOPIA 审中-公开

    公开(公告)号：US20190142778A1

    公开(公告)日：2019-05-16

    申请号：US16310587

    申请日：2017-06-21

    申请人： The University of Newcastle

    发明人： Sally Anne McFadden

    IPC分类号： A61K31/198 ,  A61P27/10 ,  A61K9/00

    摘要： Provided herein are methods for treating or preventing myopia, or for inhibiting the development of myopia, comprising administering to a subject in need thereof an effective amount of an agent capable of increasing nitric oxide levels in one or more ocular It cells or an agent capable of promoting or increasing the expression and/or activity of nNOS in one or more ocular cells. Also provided are methods for inducing or promoting nNOS expression and/or activity in one or more ocular cells, comprising exposing said cells to an effective amount of L-arginine.

    AGENT FOR TREATING EYE DISEASES
    28.
    发明申请
    AGENT FOR TREATING EYE DISEASES 审中-公开
    用于治疗眼病的药剂

    公开(公告)号：US20110223269A1

    公开(公告)日：2011-09-15

    申请号：US13039147

    申请日：2011-03-02

    申请人： Shinseiro OKAMOTO

    发明人： Shinseiro OKAMOTO

    IPC分类号： A61K36/87 ,  A61K31/05 ,  A61K31/4535 ,  A61K31/567 ,  A61P27/02 ,  A61P27/06 ,  A61P27/10 ,  A61P27/12

    CPC分类号： A61K31/56 ,  A61K31/57 ,  A61K31/724

    摘要： An agent for treating various kinds of diseases which contains at least one selected from the group consisting of sexual steroid hormone such as estrogen or its metabolites, its derivative, structural analogues thereof, estrogen acting substance or SERM non-feminizing estrogen (non-hormonal estrogen), and an activator of sirtuin and has a form of eye drops or eye washes, oral preparation, etc. An agent for treating eye diseases which has excellent treatment effects, reduced in side action can be provided.

    摘要翻译： 用于治疗各种疾病的药剂，其含有选自性激素如雌激素或其代谢物的其中的至少一种，其衍生物，其结构类似物，雌激素作用物质或SERM非女性化雌激素（非激素雌激素 ）和沉默调节蛋白的激活剂，并且具有滴眼剂或眼睛洗液的形式，口服制剂等。可以提供治疗效果优异，副作用减轻的眼部疾病的药剂。

    STABLE AQUEOUS COMPOSITIONS OF PROSTGLANDIN AGONIST PRODRUGS AND METHODS FOR USE THEREOF
    29.
    发明申请
    STABLE AQUEOUS COMPOSITIONS OF PROSTGLANDIN AGONIST PRODRUGS AND METHODS FOR USE THEREOF 审中-公开
    PROSTGLANDIN AGONIST PRODRUGS的稳定的水性组合物及其使用方法

    公开(公告)号：US20110136872A1

    公开(公告)日：2011-06-09

    申请号：US12939861

    申请日：2010-11-04

    申请人： Robert M. Burk

    发明人： Robert M. Burk

    IPC分类号： A61K31/4436 ,  A61K31/4025 ,  A61P27/02 ,  A61P27/10

    CPC分类号： A61K47/12 ,  A61K9/0048 ,  A61K31/4025 ,  A61K31/4436 ,  A61K31/559 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26

    摘要： The present invention is based on the discovery that a marked increase in aqueous stability (and thereby shelf life) of prostanoid agonist prodrug compositions is achieved by incorporating into the compositions certain well-defined carboxylic acids, and thereafter adjusting the pH of the compositions from about 4.0 to about 8.0. As a result, the compositions and methods of the invention provide the aqueous stability required for marketable topical drug treatments of a wide variety of ocular disorders.

    摘要翻译： 本发明基于以下发现：前列腺素类激动剂前药组合物的水稳定性（因此保质期）显着增加通过将组合物掺入某些明确定义的羧酸中，然后将组合物的pH从约 4.0至约8.0。 因此，本发明的组合物和方法提供了市售的局部药物治疗各种眼部疾病所需的水稳定性。